CAR-T is having a moment. The Food and Drug Administration looks poised to approve the first hot-wired white blood cell treatment from Novartis, promising to change the lives of patients with a particularly deadly form of cancer and usher in an entirely new definition of the word “drug.”
But scientists around the world are hardly standing pat in the glow of this success. Instead, they’re toiling to discover, refine, and re-invent cellular therapies for cancer in hopes of treating more tumor types, improving safety, and pushing the still-nascent field forward. Some of the most promising applications of the technology remain on the horizon — though plenty of challenges stand in the way.
Here’s a look at both the hope and the hurdles:
About the Author Reprints
is this good news for people in remission from follicular lymphoma
There’s hope.
I was one of the first adults to receive CART019 at UPenn – before Novartis and UPenn solidified their contract. I am a seven-time leukemia (ALL) survivor thanks to all who believed and contributed!
The following is an article about me from Sence About Science:
http://www.senseaboutscienceusa.org/reporting-clinical-trial-results-changed-life/#health
More info on my website:
https://nicolegularte.wordpress.com/2016/04/26/cancer-the-future-immunotherapy/